GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition
First Vaccine M&A Deal For Departing Barron
GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.
You may also be interested in...
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.